July 20 (Reuters) - Synairgen Plc SYNG.L said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.
The trial, which used interferon beta, showed that patients who were given Synairgen's formulation had a 79% lower risk of developing severe disease compared to placebo.
Patients who received the drug, SNG001, were more than twice as likely to recover from COVID-19 as those on placebo, the company said.
Interferon beta is a naturally occurring protein, which regulates the body's antiviral responses.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)
((Aakash.B@thomsonreuters.com; Twitter: @JagadeeshAakash))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.